Phase II Trial of Lung Chemoemobolization

Inclusion Criteria:

• Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinaltumors that are progressing on systemic therapy (or the patient cannot toleratesystemic therapy), and that are not amenable to resection, thermal ablation, orablative radiation therapy

• Lung-dominant disease (majority of active tumor volume is in the chest)

• At least 18 years old

Exclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status > 2

• Oxygen saturation < 92% on room air

• Forced expiratory volume in 1 second (FEV1) < 60%

• No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lungnodules are all < 1 cm)

• Life expectancy < 6 months

• Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magneticresonance imaging [MRI], or direct pressure measurement)

• Recent pulmonary embolism (within 3 months)

• Pulmonary arteriovenous malformation

• Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)

• Symptomatic heart failure (American College of Cardiology [ACC]/American HeartAssociation [AHA] stage C or D)

• Left bundle branch block (contraindication to pulmonary angiography)

• Renal failure (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m^2)

• Pregnancy or intent to become pregnant

• Breast feeding

• Altered mental status that would interfere with consent or follow-up

• Platelets < 50,000 (after transfusion, if needed)

• International normalized ratio (INR) > 2 (after transfusion, if needed)

• Hemoglobin < 7 (after transfusion, if needed)

• Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol)

• Planned radioactive iodine imaging or therapy (contraindication to lipiodol)

• Allergy to lipiodol or mitomycin

• Allergy to iodinated contrast that cannot be treated with steroid / diphenhydraminepremedication

• Any condition that, in the opinion of the investigator, would interfere withevaluation of the investigational product, or that would affect subject safety